Crohn’s & Colitis News
Below you’ll find our most recent press releases, along with other articles written by the foundation. This media content highlights the public research outcomes related to our initiatives, studies, and clinical trials. In addition, you can read our expert commentary related to research articles culled from external media sources. For a complete list of all our news content, please visit the News Archive section.
If you are a member of the media interested in speaking with a Foundation's spokesperson, contact us today.
Most Recent News
Leading Gastroenterology Organizations Announce Funding to Improve Vaccine Utilization and Preventive Health Maintenance in Patients with Inflammatory Bowel DiseasesMarch 8, 2019
The American College of Gastroenterology (ACG), the American Gastroenterological Association (AGA), and the Crohn’s & Colitis Foundation (Foundation), in partnership with Pfizer, Inc., have announced the results of a request for proposal (RFP) to address vaccine utilization, promote health maintenance, and increase preventive care services in patients with inflammatory bowel diseases (IBD).
Increased patient-provider communication affects overall outcomes at every stage of the IBD patient journeyFebruary 7, 2019
It is estimated that 3 million Americans live with inflammatory bowel disease (IBD), including Crohn’s disease (CD) and ulcerative colitis (UC). Currently, there are no cures for these diseases. For many patients their disease impacts other areas of their health and well-being including aspects of their reproductive and mental health.
For many patients the path to diagnosis and effective treatment is long and arduous, leading to delayed treatment and increased complications. Studies being presented at the Crohn’s & Colitis Congress — a partnership of the Crohn’s & Colitis Foundation and the American Gastroenterological Association, in Las Vegas, NV, on February 7-9 – reinforces the need for and highlights advances towards improved diagnosis of patients with IBD.
It is estimated that 3 million Americans live with inflammatory bowel disease (IBD), including Crohn’s disease and ulcerative colitis. Currently, there are no cures for these diseases. Studies being presented at the Crohn’s & Colitis Congress — a partnership of the Crohn’s & Colitis Foundation and the American Gastroenterological Association, in Las Vegas, NV, on February 7-9 – highlights advancement in treatments for patients with IBD.
Crohn’s & Colitis Foundation Launches New Online Journal: Crohn’s & Colitis 360 to Inform and Catalyze Patient-Centered IBD CareJanuary 23, 2019
The Crohn’s & Colitis Foundation is launching a new open access journal to engage, inform, and catalyze dialogue on state-of-the-art, comprehensive care for more than 3 million Americans living with inflammatory bowel diseases (IBD). Crohn’s & Colitis 360 is a peer-reviewed, online-only forum for the publication of novel research and insights across key disciplines in IBD care. As an open access (OA) publication, Crohn’s & Colitis 360 is free and allows unrestricted online access to research outputs with no access fees. Manuscript submissions are now open at www.crohnscolitis360.org, with the first issue slated for May.
The Crohn’s & Colitis Congress®, the premier meeting for clinical and research professionals in the IBD space, has opened registration for the 2019 meeting. A partnership of the Crohn’s & Colitis Foundation and the American Gastroenterological Association (AGA), the meeting will include four main sessions, as well as basic science sessions and pre-Congress workshops. The 2019 Crohn’s & Colitis Congress will take place February 7-9, 2019, at the Bellagio Hotel in Las Vegas.
Landmark Study to Compare the Effectiveness of Biologic or Small Molecule Therapies in Inflammatory Bowel Diseases (IBD) Receives FundingMay 17, 2018
Crohn’s disease (CD) and ulcerative colitis (UC), collectively referred to as inflammatory bowel diseases (IBD), which may affect as many as 3 million Americans, cost over $6 billion annually, and cause substantial patient morbidity, missed work and school, and diminished quality of life. Currently, anti-TNF therapy is considered first line treatment for moderate-to-severe IBD. However, up to 80 percent of patients do not respond or, ultimately, lose response to anti-TNF. New treatments provide additional options from which to choose, however, there are no head-to-head studies that compare these new treatments.